Paige Baldwin

500 total citations
24 papers, 389 citations indexed

About

Paige Baldwin is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Paige Baldwin has authored 24 papers receiving a total of 389 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 7 papers in Molecular Biology. Recurrent topics in Paige Baldwin's work include PARP inhibition in cancer therapy (20 papers), DNA Repair Mechanisms (5 papers) and Ovarian cancer diagnosis and treatment (4 papers). Paige Baldwin is often cited by papers focused on PARP inhibition in cancer therapy (20 papers), DNA Repair Mechanisms (5 papers) and Ovarian cancer diagnosis and treatment (4 papers). Paige Baldwin collaborates with scholars based in United States and Canada. Paige Baldwin's co-authors include Srinivas Sridhar, Karen T. Liby, Di Zhang, Ana S. Leal, Anne L. van de Ven, Daniela M. Dinulescu, Anders Öhman, Pier Paolo Pandolfi, Robert A. Cormack and Nina Seitzer and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Paige Baldwin

23 papers receiving 382 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Paige Baldwin United States 9 244 177 61 54 53 24 389
Jetzabel García-Parra United Kingdom 8 158 0.6× 164 0.9× 12 0.2× 29 0.5× 51 1.0× 13 313
Guillermo Nicolás Dalton Argentina 11 209 0.9× 265 1.5× 18 0.3× 40 0.7× 83 1.6× 15 503
Monika Buríková Slovakia 13 115 0.5× 262 1.5× 13 0.2× 52 1.0× 40 0.8× 14 461
Mi-Ran Choi United States 11 134 0.5× 239 1.4× 103 1.7× 41 0.8× 89 1.7× 16 528
Aparajitha Vaidyanathan United Kingdom 5 282 1.2× 246 1.4× 10 0.2× 50 0.9× 39 0.7× 7 406
Di Sun China 13 75 0.3× 290 1.6× 30 0.5× 38 0.7× 33 0.6× 29 456
Lucie Ahn United States 7 94 0.4× 286 1.6× 55 0.9× 24 0.4× 26 0.5× 10 388
Kun Mi China 11 117 0.5× 152 0.9× 54 0.9× 43 0.8× 37 0.7× 19 355
Marissa Cunetta United States 6 357 1.5× 78 0.4× 9 0.1× 25 0.5× 230 4.3× 6 467

Countries citing papers authored by Paige Baldwin

Since Specialization
Citations

This map shows the geographic impact of Paige Baldwin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paige Baldwin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paige Baldwin more than expected).

Fields of papers citing papers by Paige Baldwin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paige Baldwin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paige Baldwin. The network helps show where Paige Baldwin may publish in the future.

Co-authorship network of co-authors of Paige Baldwin

This figure shows the co-authorship network connecting the top 25 collaborators of Paige Baldwin. A scholar is included among the top collaborators of Paige Baldwin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paige Baldwin. Paige Baldwin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Arnason, Terra, Gerald F. Davies, Liubov Lobanova, et al.. (2022). Activation of the Anaphase Promoting Complex Reverses Multiple Drug Resistant Cancer in a Canine Model of Multiple Drug Resistant Lymphoma. Cancers. 14(17). 4215–4215. 4 indexed citations
3.
Rodell, Christopher B., et al.. (2020). Quantification of Cellular Drug Biodistribution Addresses Challenges in Evaluating In Vitro and In Vivo Encapsulated Drug Delivery. Advanced Therapeutics. 4(3). 7 indexed citations
4.
Baldwin, Paige, et al.. (2019). Nanoformulation of Talazoparib Increases Maximum Tolerated Doses in Combination With Temozolomide for Treatment of Ewing Sarcoma. Frontiers in Oncology. 9. 1416–1416. 20 indexed citations
5.
Baldwin, Paige, et al.. (2019). Abstract 3642: Combination nanotherapy using the PARP inhibitor talazoparib and cyclin dependent kinase inhibitor dinaciclib. Cancer Research. 79(13_Supplement). 3642–3642. 1 indexed citations
6.
Baldwin, Paige, et al.. (2019). Nanoformulation of Talazoparib Delays Tumor Progression and Ascites Formation in a Late Stage Cancer Model. Frontiers in Oncology. 9. 353–353. 19 indexed citations
7.
8.
Zhang, Di, Paige Baldwin, Srinivas Sridhar, & Karen T. Liby. (2018). Nanoformulated Talazoparib enhances the efficacy and reduces the toxicity of this PARP inhibitor in a preclinical model of BRCA‐deficient breast cancer. The FASEB Journal. 32(S1). 1 indexed citations
9.
Baldwin, Paige, et al.. (2018). In vitro analysis of PARP inhibitor nanoformulations. International Journal of Nanomedicine. Volume 13(T-NANO 2014 Abstracts). 59–61. 7 indexed citations
10.
Baldwin, Paige, et al.. (2018). Intraperitoneal delivery of NanoOlaparib for disseminated late-stage cancer treatment. International Journal of Nanomedicine. Volume 13. 8063–8074. 18 indexed citations
11.
Ven, Anne L. van de, Paige Baldwin, Ju Qiao, et al.. (2017). Nanoformulation of Olaparib Amplifies PARP Inhibition and Sensitizes PTEN/TP53- Deficient Prostate Cancer to Radiation. Molecular Cancer Therapeutics. 16(7). 1279–1289. 46 indexed citations
12.
Kumar, Rajiv, Paige Baldwin, Ana S. Leal, et al.. (2017). Sustained Release Talazoparib Implants for Localized Treatment of BRCA1-deficient Breast Cancer. Theranostics. 7(17). 4340–4349. 26 indexed citations
13.
Baldwin, Paige, et al.. (2017). Generation of Dose–Response Curves and Improved IC50s for PARP Inhibitor Nanoformulations. Methods in molecular biology. 1530. 337–342. 3 indexed citations
14.
Ven, Anne L. van de, Paige Baldwin, Ju Qiao, et al.. (2017). Abstract B48: Prostate cancer pre-treatment with nanoformulated Olaparib overcomes radiation resistance. Cancer Research. 77(2_Supplement). B48–B48. 1 indexed citations
15.
Baldwin, Paige, Rajiv Kumar, Anne L. van de Ven, et al.. (2017). Abstract B30: Sustained release of PARP inhibitor Talazoparib and chemotherapeutic Docetaxel from modified brachytherapy spacers for treatment of breast and prostate cancer. Cancer Research. 77(2_Supplement). B30–B30. 2 indexed citations
16.
Baldwin, Paige, Anne L. van de Ven, Nina Seitzer, et al.. (2016). Nanoformulation of the PARP Inhibitor Olaparib Enables Radiosensitization of a Radiation-Resistant Prostate Cancer Model. International Journal of Radiation Oncology*Biology*Physics. 96(2). E595–E595. 2 indexed citations
17.
Baldwin, Paige, Rajiv Kumar, Anne L. van de Ven, et al.. (2016). Abstract 3900: Sustained release of PARP inhibitor Talazoparib and chemotherapeutics from biodegradable implants for treatment of breast and prostate cancer. Cancer Research. 76(14_Supplement). 3900–3900. 1 indexed citations
18.
Baldwin, Paige, et al.. (2016). Abstract A03: PARP inhibitor nanotherapy for ovarian cancer.. Clinical Cancer Research. 22(2_Supplement). A03–A03. 1 indexed citations
19.
Baldwin, Paige, et al.. (2015). PARP inhibitors: A new era of targeted therapy. Maturitas. 81(1). 5–9. 115 indexed citations
20.
Maurer, L. Herbert, Thomas F. Pajak, Walter L. Eaton, et al.. (1985). Combined modality therapy with radiotherapy, chemotherapy, and immunotherapy in limited small-cell carcinoma of the lung: a Phase III cancer and Leukemia Group B Study.. Journal of Clinical Oncology. 3(7). 969–976. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jetzabel García-Parra Breakdown of academic impact, for papers by Guillermo Nicolás Dalton Breakdown of academic impact, for papers by Monika Buríková Breakdown of academic impact, for papers by Mi-Ran Choi Breakdown of academic impact, for papers by Aparajitha Vaidyanathan Breakdown of academic impact, for papers by Di Sun Breakdown of academic impact, for papers by Lucie Ahn Breakdown of academic impact, for papers by Kun Mi Breakdown of academic impact, for papers by Marissa Cunetta
Rankless by CCL
2026